Branch Retinal Vein Occlusion

Evaluation and management of branch retinal vein occlusion.

What is a Branch Retinal Vein Occlusion?

A branch retinal vein occlusion occurs when, because of hardening of the arteries, a branch retinal artery compresses a branch retinal vein causing blockage of the vein and decreased circulation in the distribution of that branch retinal vein. (see image) [note: the branch arteries are really arteriols and the branch veins are really veinules] There are several possible treatments for branch retinal vein occlusion including intravitreal injections, laser, and even surgery. Patients with BRVO lose vision for several reasons: poor circulation, hemorrhage and macular edema (swelling). There is no treatment, at the moment, to increase circulation or to remove hemorrhage. The macular edema, however, does respond well to intravitreal injections with Lucentis, Avastin, or steroids.

Read more

Lucentis for Branch Retinal Vein Occlusion

Monthly Lucentis therapy is also helpful in improving vision in patients with branch retinal vein occlusion and macular edema. Without treatment about 30 percent of have visual improvement. With treatment about 60 percent of patients have improved vision. Long term follow-up show that at 4 years, about half of the patients with branch retinal vein occlusion require continued treatment to maintain the visual benefit.


Eylea for Branch Retinal Vein Occlusion

Eylea was approved for treatment of branch retinal vein occlusion in late 2014. It is administered as an intravitreal injection monthly initially and then the treatment interval can be extended.


Branch Retinal Vein Occlusion NEWS

Below are current articles from a Google News Feed on Branch Retinal Vein Occlusion

Effect of intravitreal ranibizumab on serous retinal detachment in bra | OPTH  Dove Medical Press

Effect of intravitreal ranibizumab on serous retinal detachment in branch retinal vein occlusion Emine Dogan,1 Ozkan Sever,2 Burcin Köklü Çakir,1 Erkan Celik1 ...

India- Retinal Vein Occlusion Market 2019 Global Forecasts Analysis, Company Profiles, Competitive Landscape and Key Regions 2023 Available at Market Research Future  MENAFN.COM

(MENAFN - GetNews) Market Research Future has starting late imparted another examination to its wide research portfolio, which is titled as 'Retinal Vein ...

Retinal Vein Occlusion Market Rising Demand Seen in Healthcare at a CAGR of 11.2% by 2023 | By Types Branch Retinal Artery Occlusion, Central Retinal Vein Occlusion – Says MRFR |  Medgadget

Market Research Future published a research report on “Global Retinal Vein Occlusion Market” to track and analyses developments which are competitive in.

Protective effects of ADM-RAMP2 system make it a new therapeutic target for retinal vein occlusion  Medical Xpress

A clot in the retinal vein can lead to severe and irreversible loss of vision. In a report in the American Journal of Pathology investigators utilize a newly developed ...

Creative Planning Sells 950 Shares of Regeneron Pharmaceuticals Inc (NASDAQ:REGN)  Fairfield Current

Creative Planning trimmed its holdings in shares of Regeneron Pharmaceuticals Inc (NASDAQ:REGN) by 21.2% during the fourth quarter, according to its most ...

CIBC Private Wealth Group LLC Has $2.02 Million Position in Regeneron Pharmaceuticals Inc (REGN)  Fairfield Current

CIBC Private Wealth Group LLC decreased its holdings in Regeneron Pharmaceuticals Inc (NASDAQ:REGN) by 20.6% in the fourth quarter, according to the ...

Regeneron (REGN) to Report Q4 Earnings: Is a Beat in Store?  Nasdaq

Regeneron Pharmaceuticals, Inc . REGN is likely to beat expectations when it releases fourth-quarter and full year 2018 results on Feb 6, before the.

Anti-VEGF treatment of macular edema associated with retinal vein occl | OPTH  Dove Medical Press

Anti-VEGF treatment of macular edema associated with retinal vein occlusion: patterns of use and effectiveness in clinical practice (ECHO study report 2) J ...

Retinal Vein Occlusion Market Size and Trend by Branch and Central Retinal Vein Occlusion Type, Etc. Types and Forecast to 2023 |  Medgadget

Glaucoma is a condition where the eye pressure causes damage to the optic nerve. The increasing number of patients with glaucoma is leading the retinal vein ...

Worldwide Placenta Growth Factor Market Study for 2018 to 2023 providing information of Top Companies, Trends, Growth Factors and Industry challenges of Top 20 Countries Data  K N Hearld

Global Placenta Growth Factor Market Report speaks about the growth rate of Placenta Growth Factor market till Forecast 2023, Manufacturing process, Key ...

Regeneron Pharmaceuticals (REGN) Stock Rating Upgraded by Zacks Investment Research  Fairfield Current

Regeneron Pharmaceuticals (NASDAQ:REGN) was upgraded by Zacks Investment Research from a “hold” rating to a “buy” rating in a research report issued to ...

Research Analysts Offer Predictions for Regeneron Pharmaceuticals Inc’s Q2 2019 Earnings (REGN)  Fairfield Current

Regeneron Pharmaceuticals Inc (NASDAQ:REGN) – Analysts at Jefferies Financial Group issued their Q2 2019 earnings per share estimates for Regeneron ...

Retinal Vein Occlusion Market 2018 Highlights | By Types – Branch Retinal Artery Occlusion, Central Retinal Vein Occlusion | Top 10 Player Analysis by 2023 - Press Release  Digital Journal

Retinal Vein Occlusion Market Information: By Condition (Non-Ischemic and Ischemic), Diagnosis (Optical Coherence Tomography), Treatment and End-User ...

IOP spikes more likely after treatment in certain patients  Healio

Mild to moderate IOP spikes were seen after multiple injections of Ozurdex for treatment of uveitis, diabetic macular edema and retinal vein occlusion, but ...

Regeneron Pharmaceuticals (REGN) Stock Rating Reaffirmed by Cowen  Fairfield Current

Cowen reaffirmed their hold rating on shares of Regeneron Pharmaceuticals (NASDAQ:REGN) in a research note published on Monday, January 7th. Cowen ...

Ophthalmic Suspension Market Expected To Witness A Sustainable Growth Over 2025 By Novartis, ALLERGAN, Pfizer, Merck, Valeant Pharmaceuticals, Bayer, Genentech, Falcon Group, Ciron Drugs And Pharmaceuticals Private Limited And others  Wise Awareness

Global Ophthalmic Suspension Market Study incorporates the showcase modules ' improvement conditions and definition. The worldwide advertise is classified ...

Global Retinal Vein Occlusion Therapeutics Market Overview 2019-2025 by Manufacturers: Sanofi Aventis, Valeant Pharmaceuticals, Allergan  Industry News Source

Global Retinal Vein Occlusion Therapeutics Market Research Report evaluate worldwide market product categories, regions, with sales, Retinal Vein Occlusion ...

Canada Pension Plan Investment Board Purchased 41449 Shares of Regeneron Pharmaceuticals Inc (REGN)  BharataPress

Canada Pension Plan Investment Board lifted its stake in shares of Regeneron Pharmaceuticals Inc (NASDAQ:REGN) by 39.2% in the fourth quarter, according ...

Regeneron Pharmaceuticals (REGN) Raised to Buy at Guggenheim  Fairfield Current

Regeneron Pharmaceuticals (NASDAQ:REGN) was upgraded by equities research analysts at Guggenheim from a “neutral” rating to a “buy” rating in a research ...

Regeneron Pharmaceuticals (REGN) Scheduled to Post Quarterly Earnings on Wednesday  Fairfield Current

Regeneron Pharmaceuticals (NASDAQ:REGN) will be issuing its quarterly earnings data before the market opens on Wednesday, February 6th. Analysts expect ...

Ozurdex for retinal vein occlusion approved in China  Healio

The Chinese Food and Drug Administration has approved Ozurdex to treat adults with macular edema after branch retinal vein occlusion or central retinal vein ...

Intravitreal Diclofenac in the Treatment of Macular Edema Due to Branch Retinal Vein Occlusion  Healio

Ophthalmic Surgery, Lasers and Imaging Retina | BACKGROUND AND OBJECTIVE: To evaluate the effect of a single dose of intravitreal diclofenac on macular ...

NICE backs Bayer's Eylea as first-line BRVO treatment  PMLiVE

Bayer's Eylea (aflibercept) has been recommended for use on the NHS in England and Wales as a first-line treatment for adults with branch retinal vein ...

Branch retinal vein occlusion (BRVO) recovery: Causes, symptoms, and treatment  Bel Marra Health

Branch retinal vein occlusion or BRVO is often referred to as an “eye stroke” and can impact a person's ability to see. The degree of vision loss varies in each ...

Bayer files eye drug Eylea for new use in EU  PMLiVE

Bayer has filed an application to extend the indications of its ophthalmic drug Eylea in Europe to include use in patients with branch retinal vein occlusion ...

Young scientist helps identify cause of widespread eye disease  Science Daily

Branch retinal vein occlusion -- blockage of the blood vessels that channel blood from the retina -- is a common eye disease. A type of blood clot in the eye, the ...

Intravitreal corticosteroid implant vs intravitreal ranibizumab for th | DDDT  Dove Medical Press

Intravitreal corticosteroid implant vs intravitreal ranibizumab for the treatment of macular edema: a meta-analysis of randomized controlled trials Qingquan Wei,1 ...

Global Placenta Growth Factor Market 2019 Top Players Alteogen Inc.  GloballUp

The report on the global Placenta Growth Factor market offers complete data on the Placenta Growth Factor market. Components, for example, main players, ...

Branch Retinal Artery Occlusion (BRAO): Causes, Symptoms, Diagnosis, and Treatment  Bel Marra Health

Branch retinal artery occlusion or BRAO is a vision-related disease-causing long-term vision problems. It is caused due to reduced or blocked blood flow.

Retinal Vein Occlusion Associated With Stroke  Medscape

Retinal vein occlusion (RVO) is significantly associated with stroke development, according to a recent study. Although the investigators adjusted for potential ...

Safety, Tolerability Increases Post-Bevacizumab Injection in Intraocular Pressure  MD Magazine

New research has shown that increased IOP is tolerable to corneal endothelium, and safe for most patients' eyes despite immediate increases post-injection.

RELATE study: Increased ranibizumab, laser yield minimal benefits  Healio

BOSTON — An increased dose of ranibizumab offered no added benefit in eyes with retinal vein occlusion, according to a study presented here. Additionally ...

Surgical eye robot performs precision-injection in patient with retinal vein occlusion  Science Daily

Surgeons have operated on a patient with retinal vein occlusion using a surgical robot. Operated by an eye surgeon, the robot uses a needle of barely 0.03 ...

Retinal Vein Occlusion Market 2019 Global Forecasts Analysis, Company Profiles, Competitive Landscape and Key Regions 2023 Available at Market Research Future - Press Release  Digital Journal

"Retinal Vein Occlusion Market"Market Research Future has starting late imparted another examination to its wide research portfolio, which is titled as “Retinal ...

Retinal artery and vein thrombotic occlusion during pregnancy: markers | OPTH  Dove Medical Press

Retinal artery and vein thrombotic occlusion during pregnancy: markers for familial thrombophilia and adverse pregnancy outcomes Will S Kurtz,1 Charles J ...

Ozurdex® (dexamethasone 0.7mg) now available for millions of patients in China with macular edema secondary to retinal vein occlusion  Markets Insider

--An estimated 7.4 million people in China are living with this sight-threatening conditioni,ii,iii --. DUBLIN, March 22, 2018 /PRNewswire/ -- Today, Allergan plc ...

Should We WAVE Goodbye to Laser?  Medscape

This study helps answer a common clinical question as to whether peripheral laser to areas of retinal ischemia improves vision and reduces injection burden in ...

Biosimilars Reported Safe, Effective for Retinal Disease  Medscape

CHICAGO — Biosimilars made in India are as safe and effective for retinal vascular diseases as the American-made originator drugs, but cost about 40% less, ...

Allergan's eye implant recalled due to foreign substance  Korea Biomedical Review

Allergan is recalling Ozurdex Intravitreal Implant 700㎍ (ingredient: dexamethasone), a steroid eye implant for macular edema, after detecting a foreign ...

Dexamethasone implant for macular edema improves VA, CRT  Healio

Patients with macular edema who received a dexamethasone intravitreal implant experienced significantly improved best corrected visual acuity and central ...

Biosimilar Ranibizumab Effective in Treating RVO in a Real-World Setting  The Center for Biosimilars

In India, Razumab, manufactured by Intas Pharmaceuticals, was approved as a similar biologic to ranibizumab in 2015; the retrospective study RE-ENACT ...

Placenta Growth Factor Market Growth Opportunities by Regions, Type and Application; Trend Forecast to 2025  RISReport

Placenta Growth Factor Market 2019 Research Report including industry overview in terms of historic and present situation key manufacturers, product/*service* ...

Complications After Intravitreal Injection Aggravate  Medscape

VANCOUVER, Canada — Clusters of inflammatory responses after intravitreal injections have unnerved some specialists, who will share their experiences and ...

Risk Factors for Retinal Vein Occlusion  Medscape (subscription)

Is there a link between traditional risk factors for vascular disease and retinal vein occlusion?

Genentech Unveils Positive Phase II Results for the First-Ever Eye Implant to Achieve Sustained Delivery of a Biologic Medicine to Treat People With Wet Age-Related Macular Degeneration (AMD)  Business Wire

Genentech's investigational Port Delivery System with ranibizumab (PDS) is a small, refillable device, slightly longer than a grain of rice, surgically implanted in ...

Anti-VEGF Therapy Before Steroids for Retinal Vein Occlusion  Medscape

NICE, France — Aflibercept and ranibizumab are safer than dexamethasone intravitreal implants for the treatment of central retinal vein occlusion, a new study ...

Topical timolol-dorzolamide combined with anti-VEGF could better treat macular edema  Healio

PHILADELPHIA – An ongoing study suggests that topical timolol-dorzolamide can reduce central subfield thickness in patients with persistent macular edema ...

Altris.AI – The New Era of Retinal Diagnosis is Coming  Business Wire

Altris.AI (Altris, Inc) announced it has signed an agreement with a South Korean ophthalmic and optical medical equipment manufacturer Huvitz Co., Ltd.

Ophthalmic Suspension Market 2023: Projection of Each Major Segment, Drugs and Treatment over the Forecast Period, focusing on top key Vendors like Novartis AG, ALLERGAN, Pfizer Inc., Merck & Co., Inc., Bausch & Lomb Incorporated, Falcon Group, Valeant an  openPR

An expert on premium research reports, Market Research Future has added a report titled "Global Ophthalmic Suspension Market 2023" to its offering.

Eye strokes (retinal artery occlusion): Symptoms, causes, and treatment  Bel Marra Health

Eye strokes can come one suddenly and result in partial or complete loss of vision. Learn about cause, risk factors and treatment options.

High systolic BP affects your retina and may lead to complete vision loss  Economic Times

Constant fluctuations in the systolic pressure can lead to many major eye complications.

Placenta Growth Factor Market 2019 includes Sales Analysis, Business Region Distribution and Application in Pharma and Healthcare Industry  Global News Tribune

IndustryResearch.co provides analysis on title “Placenta Growth Factor Market (Request Sample Here)2019-2025 Analysis by Growth, Manufactures, Types, ...

Evaluation of microvascular changes in the macular area of eyes with r | OPTH  Dove Medical Press

Evaluation of microvascular changes in the macular area of eyes with rhegmatogenous retinal detachment without macular involvement using swept-source ...

Allergan Receives Approval for Ozurdex® (Dexamethasone Intravitreal Implant 0.7 mg) in China for the Treatment of Retinal Vein Occlusion (RVO)  PR Newswire

DUBLIN, Oct. 30, 2017 /PRNewswire/ -- Allergan plc (NYSE: AGN) announced today that it has received an Imported Drugs License (IDL) from the Chinese Food ...

Disorganization of Retinal Inner Layers Linked to Visual Acuity Prognoses  MD Magazine

A new study suggests patients with disorganized retinal inner layers see lesser levels of visual acuity improvement after therapy.

Aerie's (AERI) Eye Care Candidate to Enter Clinical Studies  Nasdaq

Aerie Pharmaceuticals, Inc. AERI announced that the FDA has reviewed the Investigational New Drug (IND) application for AR-1105 (dexamethasone ...

FDA to Review EYLEA (aflibercept) Injection for the Treatment of Diabetic Retinopathy  PR Newswire

TARRYTOWN, N.Y., Sept. 13, 2018 /PRNewswire/ -- Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) today announced that the U.S. Food and Drug ...

VEGF Inhibition Improves Visual Acuity in Macular Edema  Medscape

Ranibizumab improved visual acuity at 6 months in patients with macular edema secondary to ischemic branch retinal vein occlusion, whether or not they ...

Hudson Capital Management LLC Purchases Shares of 1,916 Regeneron Pharmaceuticals Inc (NASDAQ:REGN)  PressOracle

Hudson Capital Management LLC acquired a new position in Regeneron Pharmaceuticals Inc (NASDAQ:REGN) in the fourth quarter, according to its most ...

Topical Squalamine 0.2% and Intravitreal Ranibizumab 0.5 mg as Combination Therapy for Macular Edema Due to Branch and Central Retinal Vein Occlusion: An Open-Label, Randomized Study  Healio

Ophthalmic Surgery, Lasers and Imaging Retina | BACKGROUND AND OBJECTIVE:To evaluate the effects of squalamine (OHR-102; Ohr Pharmaceuticals, ...

Regeneron Gains on Eylea, Dupixent and Pipeline Progress  Nasdaq

Shares of Regeneron Pharmaceuticals Inc . REGN have gained 3.2% in the year so far against a decline of 5.9% for the industry . Tarrytown,.

Visual Prognosis of Branch Retinal Artery Occlusion  Medscape (subscription)

What is the relationship between initial visual acuity and visual prognosis in patients with branch retinal artery occlusion (BRAO)?

Aflibercept Injections Superior to Laser for Macular Edema  Medscape

Intravitreal injections of aflibercept were more effective than laser therapy for the treatment of macular edema secondary to branch retinal vein occlusion, ...

Regeneron's 12-Week Eylea Dose Gets CRL From FDA for Wet AMD  Nasdaq

Regeneron Pharmaceuticals, Inc . REGN suffered a setback when the FDA issued a complete response letter (CRL) to its supplemental Biologics License.

Placenta Growth Factor Market Analysis and In-depth Research on Market Size, Trends, Emerging Growth Factors and Regional Forecasts to 2025  Global News Tribune

Placenta Growth Factor Market 2019 Research Report including industry overview in terms of historic and present situation key manufacturers, product/*service* ...

Why Regeneron Pharmaceuticals Inc (NASDAQ:REGN) Could be Ready to Star in the Speculative Spotlight  FDA Headlines

Dec 7, 2018 | Business. Why Regeneron Pharmaceuticals Inc (NASDAQ:REGN) Could be Ready to Star in the. Regeneron Pharmaceuticals Inc ...

Regeneron's Eylea Gets FDA Nod for Wet AMD as a 12-Week Dose  Nasdaq

Regeneron Pharmaceuticals, Inc. REGN announced that the FDA has approved a supplemental Biologics License Application (sBLA) for its flagship.

Evaluation of contrast sensitivity and other visual function outcomes | OPTH  Dove Medical Press

Evaluation of contrast sensitivity and other visual function outcomes in diabetic macular edema patients following treatment switch to aflibercept from ...

Laser Speckle Flowgraphy Can Assist in CRVO Prognosis  Medscape

Laser speckle flowgraphy may offer a noninvasive method of assessing ocular blood flow in patients with central retinal vein occlusion (CRVO), according to a ...

Regeneron (REGN) Sails Steady on Label Expansion of Drugs  Zacks.com

Regeneron's (REGN) performance has been steady in the past six months even as the overall industry declines.

Similar Efficacy for Key Anti-VEGF Agents in Macular Edema  Medscape

The SCORE2 trial shows that bevacizumab and aflibercept may produce similar short-term outcomes. Here is a closer look at its results.

Visual acuity loss associated with excessive "dry macula" in exudative | OPTH  Dove Medical Press

Visual acuity loss associated with excessive "dry macula" in exudative age-related macular degeneration Hidenori Takahashi,1–3 Yuji Inoue,1,2 Xue Tan,2,3 ...

Fast Action Can Save Sight if Retina Is Detached or Blocked  New York Times

Modern treatments can do wonders if they are begun before the damage to the eye is irreversible.

Placenta Growth Factor Market: Sales Revenue and Growth Rate Forecast by Region 2018-2025  K N Hearld

Placenta Growth Factor Market 2019 Research Report including industry overview in terms of historic and present situation key manufacturers, product/*service* ...

Bayer's Eylea cleared for wider use in Europe  PMLiVE

Bayer's eye disease therapy Eylea has been cleared for a new macular oedema indication in the EU, stepping up competition against rival therapy Lucentis from ...

Regeneron (REGN) to Report Q3 Earnings: Is a Beat in Store?  Zacks.com

Investors' focus will be on the company's performance, particularly on Eylea and Dupixient's uptake during Regeneron's (REGN) third-quarter earnings call.

Ranibizumab Outperforms Aflibercept in Efficacy, Durability  MD Magazine

According to the interim results of the RIVAL trial, ranibizumab (Lucentis) showed an increase of 2.2 more letters compared to aflibercept.

Steroid Injections May Help Restore Vision In Some Patients With Blocked Eye Veins  Science Daily (press release)

Injecting the eye with the corticosteroid triamcinolone appears effective in improving the vision of some patients with retinal vein occlusion, an important cause of ...

The eye jab that can banish blind spots  Daily Mail

Clive Woodington had Central Retinal Vein Occlusion (CRVO), a distressing condition that can lead to blindness in the affected eye.

New data comparing Lucentis efficacy and durability versus aflibercept  The Pharma Letter

Swiss pharma giant Novartis (NOVN: VX) today reported new data from a Phase IV head-to-head study (RIVAL) confirming Lucentis (ranibizumab) efficacy and ...

Kodiak Sciences Announces Completion of 12-Week Phase 1a Study of KSI-301 in Patients with Diabetic Macular Edema Demonstrating Safety and Durability of Responses Following Single Dose of Intravitreal Anti-VEGF Antibody Biopolymer Conjugate  PRNewswire

PALO ALTO, Calif., Dec. 21, 2018 /PRNewswire/ -- Kodiak Sciences Inc. (Nasdaq: KOD), a clinical stage biopharmaceutical company specializing in novel...

Revealing the retina: Graphene corneal contact lens provides robust, irritation-free topographic electroretinography  Phys.org

Our vision can be damaged or lost by damage to the retina—a sensory membrane lining the back of the eye that senses light, converting the image formed into ...

Ozurdex approved for treatment of macular edema  Monthly Prescribing Reference

Allergan's Ozurdex (dexamethasone intravitreal implant) has been approved by the FDA for the treatment of macular edema following branch retinal vein ...

RETINA-AI Releases the First Artificial Intelligence Mobile App for Eye-Care Providers: Fluid Intelligence by RETINA-AI  PR Newswire

HOUSTON, July 17, 2018 /PRNewswire/ -- RETINA-AI has developed and released the first Artificial Intelligence mobile app for eye-care providers. This app ...

Monthly, PRN doses of ranibizumab similarly effective in RVO  Healio

TORONTO — As-needed and monthly ranibizumab dosing regimens yielded similar visual acuity gains in patients with retinal vein occlusion who reached a ...

New Stairway Study Data Shows Potential for Extended Durability with Faricimab in Wet Age-Related Macular Degeneration (AMD)  Associated Press

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Oct 27, 2018--Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), today ...

FDA Approves Genentech's Lucentis (ranibizumab injection) 0.3 mg Prefilled Syringe for Diabetic Macular Edema and Diabetic Retinopathy  Business Wire

First and only prefilled syringe treatment option FDA-approved to treat all forms of diabetic retinopathy in people with or without diabetic macular edema (DME) ...

European Society of Retina Specialists 17th EURETINA Congress  Medscape

European Society of Retina Specialists 17th EURETINA Congress : Read clinically focused news coverage of key developments from EURETINA 2017.

Regeneron's sBLA for Eylea Accepted by FDA, Action Date Set  Nasdaq

Regeneron Pharmaceuticals, Inc. REGN announced that the FDA has accepted for review the company's supplemental Biologics License Application (sBLA).

CRAO and Stroke Risk: Is Neurological Evaluation Warranted?  Medscape

Patients with central retinal artery occlusion may be at an increased risk for stroke and may benefit from prompt neurological evaluation, according to a new ...

RETINA-AI Releases Android Version of Fluid-Intelligence -- World's First Mobile Artificial Intelligence App for Eye Care Providers  PR Newswire

HOUSTON, Oct. 22, 2018 /PRNewswire/ -- RETINA-AI has released an Android version of its app Fluid-Intelligence, the world's first mobile artificial intelligence ...

Oculocare's Alleye® Receives FDA 510(k) Clearance for Monitoring Eyesight in AMD  PR Newswire

ZURICH, July 9, 2018 /PRNewswire/ -- Oculocare medical Inc., a Swiss technology company, announces today the FDA 510(k) clearance of Alleye®, a mobile ...

Retinal Vein Occlusion Market 2023 Analysis - Research Covers Top 10 Players as Allergan, Bayer, GlaxoSmithKline Plc, Novartis, Johnson & Johnson  openPR

Market Highlights Glaucoma is a condition where the eye pressure causes damage to the optic nerve. The increasing number of patients with glaucoma is ...

Why Regeneron Pharmaceuticals Inc (NASDAQ:REGN) Duplixant Data Came at Just the Right Time  FDA Headlines

Oct 16, 2018 | Business. Why Regeneron Pharmaceuticals Inc (NASDAQ:REGN) Duplixant Data Came at Just the Right. Regeneron Pharmaceuticals Inc ...

Pros and Cons of Compounded Pharmaceuticals | Medpage Today  MedPage Today

This article was adapted from a debate that Julia Haller, MD, and Dante Pieramici, MD, presented at the Retina Subspecialty Day prior to the 2016 American ...

Regeneron Eylea Hits 24-Week Primary Endpoint in Study  Nasdaq

Regeneron Pharmaceuticals, Inc. REGN announced positive topline results from the phase III study evaluating Eylea (aflibercept) Injection in moderately severe ...

Image processing algorithm shows promise for mapping the blood vessel networks in the eye  Phys.Org

More accurate and efficient mapping of retinal blood vessels using a path-following image processing scheme, developed by an A*STAR-led research team, ...

Treatment of refractory uveitic macular edema: results of a first and | OPTH  Dove Medical Press

Marta Zola, Cristina Briamonte, Umberto Lorenzi, Federica Machetta, Federico M Grignolo, Antonio M Fea Ophthalmic Eye Hospital, Department of Surgical ...

TPA for the Treatment of Central Retinal Artery Occlusion  Medscape

This study evaluated the outcomes of eyes with central retinal artery occlusion treated with tissue plasminogen activator, a treatment used for stroke.

Bayer receives approval for Eylea in China  The FINANCIAL

The FINANCIAL -- Bayer announced on May 11 that Eylea (aflibercept solution for injection into the eye) has been approved by the Chinese regulatory ...

» Load more